TG Therapeutics
TGTX
356 hedge funds and large institutions have $3.65B invested in TG Therapeutics in 2025 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 143 increasing their positions, 106 reducing their positions, and 63 closing their positions.
37% more call options, than puts
Call options by funds: $106M | Put options by funds: $77M
35% more repeat investments, than reductions
Existing positions increased: 143 | Existing positions reduced: 106
1.06% more ownership
Funds ownership: 62.97% → 64.03% (+1.1%)
5% less funds holding
Funds holding: 376 → 356 (-20)
6% less capital invested
Capital invested by funds: $3.9B → $3.65B (-$251M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
29% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$43.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$26.7M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$25.9M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$22.3M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$20.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$49.9M |
| 2 |
Morgan Stanley
New York
|
-$24.1M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$22.4M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$18.2M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$17.6M |
TGTX Hedge Fund Activity: Q2 2025 in Review
356 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2025, worth a combined $3.65B — down 6.4% from $3.9B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of TGTX and 45 opened new positions — a net loss of 18 holders — while 106 trimmed existing stakes and 143 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $43.1M. The largest seller was 1832 Asset Management, cutting an estimated $49.9M.
- 356 institutional investors held TG Therapeutics (TGTX) as of Q2 2025, down from 376 in Q1 2025.
- Funds reported $3.65B of TG Therapeutics stock for Q2 2025, down 6.4% quarter-over-quarter.
- 45 funds opened new TG Therapeutics positions in Q2 2025 and 63 closed out, a net change of -18 holders.
- The largest TG Therapeutics buyer in Q2 2025 was T. Rowe Price Associates, an estimated $43.1M added.
- The largest TG Therapeutics seller in Q2 2025 was 1832 Asset Management, an estimated $49.9M sold.
Based on aggregated 13F filings for Q2 2025.